ZGEN, Bayer Ink Deal for Recombinant Thrombin: #msg-20562195.
Note: this is thrombin, not antithrombin. The relevance of this deal for GTC is indirect: the deal shows that Bayer thinks recombinant thrombin will be a commercial success due to its inherent safety advantage despite the fact that plasma-derived thrombin is widely available.